Compare Crispr Therapeutics AG (CRSP) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Emerson Electric Co. — how do they compare? Crispr Therapeutics AG trades at $50.54 (market cap $4.97B), while Emerson Electric Co. trades at $136.09 (market cap $76.22B). The key difference: Emerson Electric Co. is far larger — about 15.3× Crispr Therapeutics AG's market cap, and Emerson Electric Co. pays a 1.63% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EMR | |
|---|---|---|
Market Cap | $4.97B | $76.22B |
Sector | Health | Industrials |
52-Week High | $76.78 | $161.69 |
52-Week Low | $44.34 | $123.30 |
Enterprise Value | $3.32B | $88.49B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Emerson Electric (EMR) trades at $135.38, down 2.52% on the day, with a bearish technical signal and mixed earnings history. The stock shows moderate valuation ratios (P/E 31.34, P/S 4.17) and stable profitability (net margin 13.35%). Recent news highlights upcoming Q3 2026 earnings and dividend activity, while cash flow trends indicate operational strength but net outflows.
The outlook is cautiously optimistic with a consensus price target of $157.60 (16.4% upside), supported by analyst buy ratings (51.2%). Key risks include volatile cash flows and competitive pressures in manufacturing electronics. Earnings growth and sector momentum remain catalysts for potential appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
